Centrexion Therapeutics, which is developing non-opioid therapies for chronic pain, withdrew its plans for an initial public offering on Wednesday. It had originally filed to raise $75 million by offering 5 million shares at a price range of $14 to $16 in November 2018, before postponing the deal later that month. The company had not filed an update since December 2019.
The Boston, MA-based company was founded in 2013 and planned to list on the Nasdaq under the symbol CNTX. Credit Suisse and SVB Leerink were set to be the joint bookrunners on the deal.
